The only triple agonist — next generation beyond GLP-2TZ's dual approach. 30+ published studies (rapidly growing). 99%+ HPLC-verified purity. 3-lab independent COA on every batch.
GLP-3 RT (LY3437943) is the world's first triple incretin receptor agonist, simultaneously activating GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This three-pathway mechanism represents the next evolution beyond GLP-2TZ's dual GLP-1/GIP approach and GLP-1SM's single GLP-1 mechanism.
The addition of glucagon receptor agonism is theorized to enhance energy expenditure and hepatic lipid metabolism beyond what GLP-1 and GIP alone can achieve. Published research has demonstrated unprecedented preclinical results in metabolic models, making GLP-3 RT one of the most closely watched compounds in metabolic research.
GLP-3 RT is classified as a research-use-only compound. It is not FDA-approved for any therapeutic indication. All references below describe preclinical and clinical research contexts, not therapeutic recommendations.
The defining feature of GLP-3 RT — simultaneous GLP-1, GIP, and glucagon receptor agonism in a single molecule. Research examines the synergistic effects of triple-pathway metabolic signaling.
Published studies examine GLP-3 RT's effects on energy balance, appetite signaling, and metabolic rate through its unique triple-receptor mechanism. The glucagon component adds thermogenic signaling absent in dual agonists.
Research investigates GLP-3 RT's influence on insulin sensitivity, glucose disposal, and glycemic control through complementary GLP-1 and GIP pathway activation in metabolic disruption models.
The glucagon receptor component is studied for its effects on hepatic lipid oxidation and triglyceride metabolism — a pathway not engaged by GLP-1-only or dual GLP-1/GIP compounds.
GLP-3 RT (LY3437943) is a triple incretin receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. It is the only triple agonist in existence — representing the next generation beyond GLP-2TZ's dual GLP-1/GIP approach and GLP-1SM's single GLP-1 mechanism.
GLP-1SM activates 1 receptor (GLP-1). GLP-2TZ activates 2 receptors (GLP-1 + GIP). GLP-3 RT activates 3 receptors (GLP-1 + GIP + Glucagon). The addition of glucagon receptor agonism adds thermogenic and hepatic lipid-oxidation pathways not engaged by single or dual agonists.
Triple agonism means simultaneous activation of three metabolic receptors: GLP-1 (satiety, insulin secretion), GIP (incretin amplification, fat tissue signaling), and Glucagon (hepatic lipid oxidation, thermogenesis, energy expenditure). This multi-pathway approach produces complementary metabolic effects in research models.
Research-grade GLP-3 RT with 3-lab COA verification is available at SMART MD Peptides in 10mg and 20mg formulations. Every batch is publicly verifiable at smartmdpeptides.com/verify before purchase. 99%+ HPLC purity guaranteed.
Lyophilized (unreconstituted) GLP-3 RT should be stored at -20°C, protected from light. Once reconstituted, store at 2-8°C and use within the timeframe specified on your lot-specific documentation.
Check the COA before you buy. Compare it against any other supplier's documentation.